Skip to main content
Premium Trial:

Request an Annual Quote

Analyst Begins Covering Fisher, Says Record of Growth Warrants Outperform Rating

NEW YORK, June 3 (GenomeWeb Daily News) - An analyst for Leerink Swann  initiated coverage of Fisher Scientific, and has given the company an 'Outperform' rating, the investment bank said today.


John Sullivan, senior biotechnology and life sciences analyst for Leerink Swann said Fisher's "record of internal and acquired growth, the expansion of its strong franchise in life science consumables, and its strategy of adding higher margin products to its mix" fueled his decision.


Fisher acquired  proteomics shop Perbio in 2003 and  RNAi tools provider Dharmacon one year later. As GenomeWeb News reported last week, the company said it is eyeing potential acquisitions as it continues to look for ways to grow its footprint in the life-sciences market.


Fisher said it is focusing on higher-growth consumables plays in the molecular biology tools field, Vice Chair Paul Meister said during a recent investor conference.


He said Fisher expects $400 million in cash flow this year, which would ensure the company is flexible for any potential acquisition targets that come its way.

The Scan

J&J Booster Support

A US Food and Drug Administration advisory panel has voted to support a booster dose of Johnson & Johnson's SARS-CoV-2 vaccine, according to the Los Angeles Times.

To Keep the Cases Moving

The president of the UK Royal College of Pathologists tells the Financial Times that more investment is needed to tackle a backlog of cases.

NAS Expels Archaeologist

Science reports Luis Jaime Castillo Butters' expulsion is the first of an international member from the US National Academy of Sciences.

PLOS Papers on Angelman Syndrome-Like Cases, Salmonella Paratyphi A, SARS-CoV-2 in Brazil

In PLOS this week: exome sequencing analysis of Angelman syndrome-like cases, genetic epidemiology of Salmonella Paratyphi A, and more.